The U.S. Food and Drug Administration (FDA) has approved dupilumab (Dupixent, Sanofi & Regeneron) to treat adults with bullous pemphigoid (BP). This is the first and only targeted medicine to treat BP in the U.S. Margaret Bobonich, DNP, FNP-C, DCNP, FAANP, Founder of the Center for Dermatology NP PA, discusses the significance of this approval and what it will mean for BP patients.
